Clin Cancer Res: The efficacy of Narvon anti-fir alcohol and reed anti-treatment for advanced stomach cancer is available in the future!

Stomach cancer is the fifth highest rate of mutation in so many cells.
PD-1, PD-L1 and their ligate over-expressions in stomach cancer cells and cancerous tissue-soaked T cells.
the efficacy of anti-PD-1/PD-L1 antibodies in advanced stomach cancer (AGC) has not been definitive.
study is a Phase 1/2 clinical trial designed to study the safety and efficacy of Narvon and yew alcohol in a joint Remo reed monoantigen for AMC.
the research process and dose recruits patients with advanced stomach cancer who have difficulty treating first-line chemotherapy to be treated with navuda (3 mg/kg, day 1 and 15) in combination with yew alcohol (80 mg/m2, 1/8 and 15 days) and remoly monoantigen (8 mg/kg, day 1 and 15), with a course of treatment every 4 weeks.
assessed the feasibility (Phase I) in six patients, the Phase II section recruited an additional 37 patients, with the main endpoint being six months of progressopathic survival (PFS).
joint positive score (CPS) defined as the percentage of programmed death ligative 1 positive cells to the total number of surviving tumor cells.
major prognostics: A:PFS;
, 60.5% of patients had a CPS ≥ 1 point.
toxicity was observed in two patients, and the recommended dose was set at level 1.
39 patients (90.7%) had ≥ level 3 treatment-related side effects (AE) and 14 patients (32.6%) had ≥3 level immune-related AE.
the total prognosmision rate for different groupings was 37.2% (95% CI 23.0%-53.5%) and the six-month PFS rate was 46.5% (80% CI 36.4%-55.8%, p=0.067).
survival time was 13.1 months: 13.8 months for patients with CPS≥1 and 8.0 months for patients with CPS-lt;1.
above, Narvon and yew alcohol combined with remortain resistance are used in ADC patients as second-line therapies to show future predictable anti-tumor activity and controllable toxicity.
。